₩10,000.00 ($7.44)

-30.00 (-0.30%)

Weekly Expected Move ±1.7%

₩9666 ₩9833 ₩10000 ₩10167 ₩10334

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 35 · ₩147.0B mcap · 5M float · 1.07% daily turnover

Revenue

$566.3B -19.6% ▼

5Y CAGR: -3.9%

Gross Profit

$208.4B +17.4% ▲

5Y CAGR: +5.9%

Operating Income

$20.7B +209.3% ▲

5Y CAGR: +9.9%

Net Income

$23.4B +178.0% ▲

5Y CAGR: +27.6%

EPS (Diluted)

$1604.77 +178.0% ▲

5Y CAGR: +27.7%

EBITDA

$32.6B +407.8% ▲

5Y CAGR: +7.6%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$700.7B	$722.2B	$726.4B	$704.5B	$566.3B
YoY Growth	+1.4%	+3.1%	+0.6%	-3.0%	-19.6%
Cost of Revenue	$544.7B	$565.4B	$542.1B	$527.0B	$358.9B
Gross Profit	$156.0B	$156.8B	$184.3B	$177.5B	$208.4B
Gross Margin	22.3%	21.7%	25.4%	25.2%	36.8%
R&D Expenses	$39.0B	$41.1B	$45.7B	$38.8B	$0
SG&A Expenses	$74.7B	$74.6B	$76.5B	$82.8B	$0
Operating Expenses	$166.4B	$170.1B	$175.5B	$196.4B	$188.1B
Operating Income	-$10.4B	-$13.5B	$8.7B	-$18.9B	$20.7B
Operating Margin	-1.5%	-1.9%	1.2%	-2.7%	3.7%
Interest Expense	$2.0B	$3.0B	$6.0B	$5.1B	$4.4B
Income Before Tax	-$13.8B	-$13.2B	$1.9B	-$27.5B	$35.0B
Tax Expense	$1.2B	$1.8B	-$3.3B	$3.2B	$2.9B
Net Income	-$12.5B	-$13.1B	$5.0B	-$30.0B	$23.4B
Net Margin	-1.8%	-1.8%	0.7%	-4.3%	4.1%
EPS (Diluted)	$-853.81	$-898.19	$343.46	$-2056.36	$1604.77
EBITDA	-$2.0B	-$1.2B	$17.7B	-$10.6B	$32.6B
Shares Outstanding	15M	15M	15M	15M	15M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$174.4B	$186.6B	$163.0B	$137.6B	$134.8B	$131.8B	$130.3B	$146.6B
Cost of Revenue	$136.5B	$134.9B	$110.8B	$84.2B	$80.2B	$79.1B	$79.7B	$87.6B
Gross Profit	$37.9B	$51.7B	$52.3B	$53.4B	$54.6B	$48.2B	$50.6B	$59.0B
Gross Margin	21.7%	27.7%	32.1%	38.8%	40.5%	36.6%	38.8%	40.3%
R&D Expenses	$9.4B	$9.2B	$9.6B	$11.1B	$9.6B	$14.4B	$14.0B	$21.2B
SG&A Expenses	$20.1B	$23.5B	$36.6B	$48.7B	$21.2B	$22.2B	$23.3B	$44.7B
Operating Expenses	$42.0B	$49.3B	$46.6B	$48.7B	$44.7B	$52.0B	$50.5B	$66.3B
Operating Income	-$4.1B	$2.4B	$5.7B	$4.7B	$9.8B	$407M	$43M	-$7.3B
Operating Margin	-2.3%	1.3%	3.5%	3.4%	7.3%	0.3%	0.0%	-5.0%
Interest Expense	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.2B	$1.2B
Income Before Tax	-$5.3B	$4.2B	$4.8B	$3.7B	$17.7B	$8.8B	$3.2B	-$11.1B
Tax Expense	$163M	-$2.1B	$1.1B	$633M	$1.8B	-$665M	$9M	-$4.4B
Net Income	-$4.2B	$3.6B	$2.6B	$3.1B	$10.3B	$7.4B	-$310M	-$8.0B
Net Margin	-2.4%	1.9%	1.6%	2.3%	7.6%	5.6%	-0.2%	-5.5%
EPS (Diluted)	$-288.00	$248.39	$179.77	$214.39	$705.00	$505.40	$-21.19	$-545.23
EBITDA	-$1.3B	$8.0B	$8.9B	$56.3B	$22.0B	$3.5B	$3.3B	-$3.9B
Shares Outstanding	15M	15M	15M	15M	15M	9M	15M	15M

271980.KS KSC